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Vasopressin in perioperative management of
congenital diaphragmatic hernia: a case report
Andra Malikiwia, Peter Fergusonc and Arvind Sehgala,b
Perioperative care of infants with diaphragmatic hernias
can be a challenge because of pulmonary hypertension
and systemic hypotension. The objective of this study was
to report the usefulness of vasopressin infusion in
improving pulmonary and systemic haemodynamics in an
infant with congenital diaphragmatic hernia. Oxygenation
failure, pulmonary hypertension and refractory systemic
hypotension in infants with diaphragmatic hernia are
managed by ventilation and conventional inotropes
(dobutamine and dopamine). Vasopressin is a recent
addition that exerts vasodilatory effects on the pulmonary
circulation and vasotonic effects on the systemic
circulation. The net effect is a reduction in pulmonary
vascular resistance and improvement in cardiac output and
reduced need for inotropes. This paradoxical response
(vasodilation in some vascular beds) distinguishes it from
other vasoconstrictor agents. The infant was administered
intravenous vasopressin infusion for severe pulmonary
hypertension that needed inhaled nitric oxide and for
systemic hypotension that needed multiple inotropes
under close echocardiographic monitoring. Informed
parental consent and appropriate institutional ethics
approval were obtained. Addition of vasopressin led to
improved oxygenation and weaning off from nitric therapy.
Improvement in cardiac output and blood pressure
facilitated the weaning off from inotropes. Close
echocardiographic monitoring was performed to ascertain
the haemodynamic effects of vasopressin. Under
echocardiographic monitoring, vasopressin is a useful
adjunct for managing pulmonary and systemic
perioperative haemodynamic instability in infants with
diaphragmatic hernia. Ann Pediatr Surg 13:47–49 c 2017
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Introduction
Clinical outcomes in infants with congenital diaphrag-
matic hernia (CDH) may be affected by pulmonary
hypoplasia, pulmonary hypertension and associated pre-
sence of congenital heart disease. Additionally, some
infants may develop severe oxygenation failure and
refractory systemic hypotension, making the management
extremely challenging. Inhaled nitric oxide as a pulmon-
ary vasodilator and conventional inotropes (dobutamine
and dopamine) are generally used to establish and
maintain haemodynamic stability. Vasopressin has been
shown to be efficacious in relieving hypoxic pulmonary
vasoconstriction and for the treatment of refractory
systemic hypotension [1–3].
This case report details the usefulness of intravenous
vasopressin infusion given under close functional echo-
cardiographic monitoring in improving pulmonary and
systemic haemodynamics.
Case report
An antenatal ultrasound performed in a G3P1 mother at
204 weeks’ gestational age showed a left-sided CDH. An
obstetric MRI 6 weeks later noted the spleen, a part of
the liver and most of the small bowel and most of the
transverse and descending colon and stomach to be in the
thorax. The ratio between the observed and the expected
total lung volume was 0.33.
This baby girl was born by caesarian section at 365 weeks’
gestational age due to nonreassuring foetal trace, and
weighed 3344 g. She was immediately intubated and
mechanically ventilated and a Replogle tube was inserted
to decompress the stomach. Umbilical venous and arterial
catheters were inserted for parenteral nutrition and
invasive blood pressure monitoring. Sedation and muscle
relaxation was administered using morphine and atracur-
ium infusions. Conventional ventilation was changed to
high-frequency ventilation after 30 min because of
oxygenation failure and CO2 retention. A wide presatura-
tion and postsaturation gradient suggested pulmonary
hypertension, which was confirmed by echocardiography;
no congenital heart disease was noted. Inhaled nitric
oxide was started at 20 ppm, which reduced the satura-
tion gradient. Systemic hypotension was managed by
escalating doses of dobutamine and dopamine. Vasopres-
sin infusion was started at a dose of 0.04 U/kg/h
(equivalent to 0.0006 U/kg/min). Table 1 and Fig. 1
depict the evolution of various parameters before and
after vasopressin therapy. A dramatic improvement was
noted over the next few hours in the oxygenation index,
which was accompanied by improvements in biventricular
cardiac output, blood pressure and pulmonary hyperten-
sion. The suprasystemic pulmonary pressures turned
subsystemic and remained so after cessation of vasopres-
sin. Nitric therapy and inotropes were gradually weaned
off. The infant was operated on the fifth postnatal day. A
type C defect in the left hemidiaphragm was managed
with primary repair [4]. Vasopressin was continued during
surgery, with no desaturations/pre–post saturation
gradient or system hypotension noted intraoperatively.
Case report 47
1687-4137 c 2017 Annals of Pediatric Surgery DOI: 10.1097/01.XPS.0000489147.17551.89
Copyright r 2017 Annals of Pediatric Surgery. Unauthorized reproduction of this article is prohibited.
The patient was weaned off it from the third post-
operative day over a further 48 h and she was extubated
24 h after cessation of vasopressin. No rebound pulmon-
ary hypertension or systemic hypotension was noted. The
postoperative period was complicated by a mild would
infection, which was accompanied by a raised C-reactive
protein level, and was managed with vancomycin for a
period of 5 days. Hyponatremia was managed with fluid
restriction and sodium supplementation; it resolved
rapidly after vasopressin cessation and she was discharged
home after establishment of oral feeds. The study was
approved by the institution’s ethics board, and written
informed consent was obtained from the parents.
Discussion
Newborn infants with CDH can be extremely sick and
sometimes require extracorporeal membrane oxygenation
(ECMO). In this case, vasopressin therapy was associated
with significant and dramatic improvement in pulmonary
and systemic haemodynamics (improved oxygenation,
reduced pulmonary hypertension and weaning off from
nitric therapy along with improved blood pressure and
weaning off from inotropes). Vasopressin usage was
monitored by functional echocardiography.
Vasopressin analogue (terlipressin) use in CDH and
pulmonary hypertension was first reported by Papoff
et al. [5]. Others have reported its usage in nitric-
unresponsive pulmonary hypertension secondary to me-
conium aspiration and in critically ill catecholamine-
unresponsive patients with hypotension due to septic
shock [1,6]. Its vasodilatory actions in the pulmonary
circulation are mediated by the activation of endothelial
oxytocin receptors, which in turn triggers activation of
nitric oxide synthase [7]. Towards the systemic side, it
Table 1 Echocardiographic parameters during the perioperative course






through PDA SBP RVSP/SBP
Left ventricular
SV (ml/kg)
1 3.9 3.6 65.7 0.9 63 62 1.06 0.5
2 3.6 3.4 56.2 1.12 28 72 0.78 0.8
3 3.5 2.9 44 1.36 19 62 0.7 1.1
4 2.9 2.8 41 1.34 20 72 0.6 1.2
5 Surgery
6 2.9 3.2 50 1.5 0 75 0.6 1.3
8 2.6 2.1 22.6 1.8 0 70 0.3 1.45
11 2 2.1 22.6 1.9 0 75 0.3 1.5
28 Closed 1.7 16.6 1.9 0 68 0.2 1.5
PDA, patent ductus arteriosus; RTL, right to left; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure; SV, stroke volume; TR, tricuspid regurgitation.
aUsing modified Bernoulli’s equation.
Fig. 1
Evolution of oxygenation index, nitric therapy and inotropic support before and after vasopressin administration.
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exerts vasotonic effects, which are mainly mediated by
activation of V1 vascular receptors and modulation of
ATP-sensitive potassium channels. This paradoxical
action on differing circulations, in some ways, makes it
an ideal agent in situations of pulmonary hypertension
and oxygenation failure coexisting with systemic hypo-
tension. Its role becomes significant especially in infants
too sick to be transported for ECMO or when such a
facility is not available. In a recent retrospective case
series assessing the efficacy of vasopressin in stabilizing
haemodynamics in CDH infants, vasopressin was seen to
increase blood pressure, decrease the pulmonary to
systemic pressure ratio, and oxygen requirement. In six
of 13 infants, ECMO was no longer needed. Transient
hyponatremia resolved with fluid restriction and sodium
supplementation [8].
As experience with vasopressin is limited, close haemody-
namic monitoring is desirable to document the pulmonary
and systemic cardiovascular parameters. Relevant para-
meters are depicted in Table 1. Briefly, pulse Doppler
assessment of the main pulmonary artery can give
information about the right ventricular output. Greater
than 30% duration of right-to-left shunting through the
patent ductus arteriosus as a percentage of time of the
cardiac cycle suggests significantly elevated pulmonary
pressure [9]. Maximum velocity of the tricuspid regurgita-
tion jet is used to estimate the right ventricular systolic
pressure using modified Bernoulli’s equation. Left ventri-
cular stroke volume is a useful systemic index that
complements invasively measured blood pressure. Vaso-
pressin therapy resulted in the improvement of biventri-
cular parameters (lowering of ductal right-to-left shunting
and tricuspid regurgitation velocity and improved cardiac
outputs).
Vasopressin is a useful adjunctive therapy for the
management of critically ill infants with CDH-associated
pulmonary hypertension and systemic hypotension.
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